This article needs additional citations for verification. (July 2019) (Learn how and when to remove this template message) |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 4–16 days |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C16H16F3NO |
| Molar mass | 295.30 g/mol g·mol−1 |
Seproxetine, also known as (S)-norfluoxetine, is a selective serotonin reuptake inhibitor (SSRI).[1] It is the most important active metabolite of the widely used antidepressant fluoxetine, but little is known about its pharmacological actions. Seproxetine was being investigated by Eli Lilly and Company as an antidepressant; however, a cardiac side effect was noted and development was discontinued.
References
- ^ "Seproxetine". DrugBank. University of Alberta. Retrieved 10 August 2016.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |